A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data

NCT06877884 · tracked via the Priya Life Science USA tracker

Sponsor

N-Power Medicine

Phase

Observational

Started

2022-08-01

Last updated

2025-10-20

Condition(s) studied

Cancer

Study summary

This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.

Eligibility

Sex

ALL

Min age

18 Years

Max age

120 Years

Healthy volunteers

Accepted

Inclusion Criteria: Be a patient at a site (oncology) participating in the Registry Be at least 18 years old Be able and willing to provide signed informed consent Exclusion Criteria: Prisoners/imprisonment at time of screening for eligibility Patients who cannot consent without utilization of a legally authorized representative

Primary outcome measure(s)

Treatment Effectiveness - Time to treatment discontinuation — This is an open-ended registry where data will be collected, analysed and presented regularly over time.
Effectiveness outcomes of treatments used in routine clinical care (such as for instance time to treatment discontinuation ) will be captured

Trial sites (7)

Facility	City	Region	Status
Pacific Cancer Care	Monterey	California	Recruiting
Bayhealth Cancer Center-Kent	Dover	Delaware	Recruiting
Bayhealth Cancer Center- Sussex	Milford	Delaware	Recruiting
Northwest Oncology & Hematology	Elk Grove Village	Illinois	Recruiting
New Mexico Oncology Hematology Consultants	Albuquerque	New Mexico	Recruiting
Lankenau Medical Center	Paoli	Pennsylvania	Recruiting
Oncology Consultants, P.A.	Houston	Texas	Recruiting

More N-Power Medicine trials in the USA

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer Recruiting

An External Control Arm Study in Non-Small Cell Lung Cancer Recruiting

Other trials for the same condition

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting

xDRIVE for Florida-based Cancer Patients Recruiting

Caris Biorepository Research Protocol Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) Recruiting

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06877884 on ClinicalTrials.gov ↗ ← All trials in the USA